secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-06-04T23:59:59+00:00
Accession:  0001193125-24-153625
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Phase 3 GBS trial meets primary endpoint; ANX005 shows 2.4-fold improvement on GBS-DS at week 8
--------------------------------------------------------------------------------

- Phase 3 trial met primary endpoint: single infusion of ANX005 30 mg/kg achieved 2.4-fold improvement on GBS-DS at week 8 (p=0.0058).
- Key secondary endpoints met: 28 fewer days on ventilation (p=0.0356), 31-day reduction in time to walk independently (p=0.0211), and early muscle strength gains.
- ANX005 was generally well-tolerated; most adverse events mild-to-moderate, no drug-related deaths or serious infections.
- RWE comparability protocol initiated with IGOS; BLA submission and RWE data expected first half 2025.
- GBS affects >22,000 hospitalized annually in U.S./Europe; no FDA-approved treatments currently.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524153625/0001193125-24-153625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524153625/d838099d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-153625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer